Company Overview of Caprion Proteomics, Inc.
Caprion Proteomics, Inc. provides proteomics and immune monitoring services to the pharmaceutical and biotechnology industry in North America, Europe, and Asia. Its capabilities include study design, sample preparation, statistical analysis, biological interpretation, and reporting. The company’s expertise also includes the discovery, qualification, and verification of pharmacodynamic/predictive biomarkers and disease markers in various phases of clinical/pre-clinical studies; multiple reaction monitoring assay development for the rapid multiplexed verification and validation of biomarkers; differential expression studies; protein characterization; host cell protein assays for manufacturing ...
201, avenue Président-Kennedy
Montreal, QC H2X 3Y7
Founded in 2002
Key Executives for Caprion Proteomics, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Senior Vice-President
Senior Vice-President of Scientific Operations
Chief Business Officer and Senior Vice-President
Senior Vice-President of Corporate Development and Diagnostics
Compensation as of Fiscal Year 2015.
Caprion Proteomics, Inc. Key Developments
Caprion Proteomics Announces Study Results on Development of Blood-Based Diagnostic for Lung Cancer Yields Publication in Science Translational Medicine
Oct 16 13
Caprion Proteomics announced the results of a major study conducted by Indi (Integrated Diagnostics) which suggests that quantification of a combination of blood proteins can accurately distinguish between benign lung nodules and early-stage lung cancer. The study, which was published in Science Translational Medicine (STM) and includes several Caprion scientists as co-authors, indicates that when the relative concentrations of this group of proteins (or 'classifier') is combined, the classifier result is correct more than 90% of the time in diagnosing benign lung nodules. This multiple protein classifier uses a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec). The laboratory-based analytical method, combined with sophisticated bioinformatics and systems-biology approaches allowed the researchers to assess the diagnostic power of 371 potential lung cancer biomarkers in millions of different combinations before settling on the diagnostic classifier (set of biomarkers) that these data indicate is most effective.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries